ISSN 0006-2979, Biochemistry (Moscow), 2026, Vol. 91, No. 10, pp. 1822-1841 © Pleiades Publishing, Ltd., 2026.
1822
REVIEW
When the Brain Signals Danger:
Roles ofCalreticulin and HMGB1 in Cell Death
Mechanisms inNeurooncology and Neurodegeneration
Tatiana A. Mishchenko
1
, Anna A. Grechukhina
1
, Sergey S. Kulikov
1
,
Oluwabukolami Joy Olajide
1
, Elena V. Mitroshina
1
, Dmitri V. Krysko
2,3&#
,
and Maria V. Vedunova
1,a
*
#
1
Institute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod,
603022 Nizhny Novgorod, Russia
2
Cell Death Investigation and Therapy (CDIT) Laboratory, Anatomy and Embryology Unit,
Department of Human Structure and Repair, Faculty of Medicine and Health Sciences,
Ghent University, 9000 Ghent, Belgium
3
Cancer Research Institute Ghent, 9000 Ghent, Belgium
a
e-mail: mvedunova@yandex.ru
Received May 18, 2026
Revised July 13, 2026
Accepted July 14, 2026
Abstract— Contrary to the classical paradigm of brain immune privilege, damage-associated molecular pat-
terns (DAMPs) act as key mediators in the dialogue between CNS cells and the immune system, determin-
ing pathways of immune response development. This review examines the role of key DAMPs – calreticulin
(CRT) and high-mobility group box 1 protein (HMGB1) – in the functioning of CNS under normal conditions
and during the development of neuropathologies, particularly oncological and neurodegenerative processes.
Under normal conditions, CRT and HMGB1 ensure functioning of the brain, acting as necessary effectors of
neurogenesis and homeostatic plasticity. In neurooncology, exposure of CRT on the surface of dying cells and
release of HMGB1 serve as powerful adjuvant signals for antigen-presenting cells, inducing immunogenic cell
death (ICD). Particular attention is given to the mechanisms of passive HMGB1 release during various types of
regulated cell death (apoptosis, necroptosis, pyroptosis, ferroptosis, cuproptosis), as well as to the role of redox
modifications of the protein, which determine its pro-inflammatory, immunogenic, or tolerogenic properties.
Inneurodegeneration (Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis), excessive DAMP
release exacerbates the development of chronic neuroinflammation, disrupts integrity of the blood-brain bar-
rier (BBB), and forms a vicious cycle of pathological changes. Detection of CRT and HMGB1 in biological fluids
or brain tissues has important prognostic potential, and regulation of their signaling pathways opens promising
approaches for overcoming tumor resistance or inhibiting progressive neurodegenerative changes in the brain.
DOI: 10.1134/S0006297926601565
Keywords: regulated cell death, immunogenic cell death (ICD), damage-associated molecular patterns (DAMPs),
calreticulin (CRT), HMGB1, brain tumors, neurodegenerative diseases
* To whom correspondence should be addressed.
# These authors contributed equally to this study.
& Deceased.
INTRODUCTION
For a long time, immunology was dominated
by the idea that activation of the immune response
occurs according to the “self vs non-self” principle.
In the late 19th century, I. I. Mechnikov discovered
the process of phagocytosis of foreign material and
described one of the main mechanisms of innate
immunity. In 1989, Charles Janeway proposed the
concept of “pattern recognition” (Fig.  1), describ-
ing specific recognition of the conserved pathogen
molecules, called pathogen-associated molecular
DAMPs IN THE CNS 1823
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
Fig.  1. From PAMPs and DAMPs to regulation of immune response and cell death: brief chronology of key discoveries.
patterns (PAMPs)  [1]. PAMPs are recognized by the
pattern-recognition receptors (PRRs), are encoded in
the germline and expressed by the innate immune
cells, which triggers an inflammatory response and
protects the host from pathogen invasion  [1]. Later,
other factors leading to initiation of the immune re-
sponse were discovered, mediating development of
the so-called sterile (i.e., non-infectious) inflamma-
tion. In 1994, Polly Matzinger (Fig.  1) proposed the
“danger theory”, according to which the key task for
the immune system is to identify and neutralize “dan-
ger”, which could be bacterial toxins, viruses, tumor
processes, or unprogrammed cell death  [2].
Later, the author suggested a more generalized
term for the immune response inducers as “danger
signals from the damaged or stressed cells”  [3], and in
2003, Walter Land expanded this concept to the term
“damage-associated molecular patterns” (DAMPs)  [4].
Unlike PAMPs, DAMPs comprise a heterogeneous
group of endogenous molecules, including proteins,
lipids, nucleic acids, which ensure normal function-
ing of the cell. In endogenous and exogenous dam-
age, DAMPs could function as danger signal trans-
mitters through open hydrophobic fractions and
regulate both innate and adaptive immune respons-
es  [5]. If the level of stress exceeds the cell’s repair
capacity, regulated cell death is triggered (Table  1).
The nature of this death may be silent, tolerogenic,
inflammatory, or immunogenic, depending on the
mechanism of cell death, the presence of antigens and
adjuvants, and the characteristics of the microenvi-
ronment  [6].
In infection, stress, or cell death, DAMPs are re-
located to the extracellular space, where they could
interact with PRRs, such as Toll-like receptors (TLRs),
NOD-like receptors (NLRs), retinoic acid-inducible
gene I (RIG-I)-like receptors (RLRs), C-type lectin re-
ceptors (CLRs), and others  [7]. DAMPs could also be
recognized by the receptor for advanced glycation
end products (RAGE), triggering receptors expressed
on the myeloid cells (TREMs), and by the G-pro-
tein-coupled receptors (GPCRs) [8-10]. Depending on
the initiating stress, which determines the mechanism
of cell death, the dynamics of DAMP release, their
combinations with other molecules, and microenvi-
ronment, all these factors could have a dual role in
the development of the immune response.
On the one hand, DAMPs could act as adjuvants
for antigen-presenting cells, promoting activation of
their phagocytic activity and maturation, as well as
subsequent presentation of antigens by the major his-
tocompatibility complex class I (MHC I) molecules to
the CD8
+
T cells, leading to formation of an adaptive
immune response and long-term immunological mem-
ory. This mechanism is called immunogenic cell death
(ICD) (Table  1)  [13]. To date, immunogenic properties
have been shown for apoptosis, as well as other
types of regulated cell death, including necroptosis,
ferroptosis, pyroptosis, and the recently discovered
cuproptosis (Table  1). Induction of ICD is considered
MISHCHENKO et al.1824
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
Table  1. Types of regulated cell death with immunogenic properties: a brief glossary
Name Characteristics References
Regulated
cell death
a form of cell death initiated by activation of one or several signaling
pathways, which could be partially or completely inhibited/enhanced
as a result of genetic or pharmacological interventions, both under normal
conditions and during the development of pathologies
[11]
Programmed
cell death
a form of regulated cell death activated only under natural physiological
scenarios as part of a genetically encoded program for the development
of homeostasis in an organism
[11]
Accidental
cell death
(accidental
necrosis)
an unregulated type of cell death caused by extreme physicochemical stress
(e.g., thermal shock, severe freeze-thaw cycles) or mechanical damage;
accompanied by the release of DAMPs into the extracellular space but lacks
immunogenic properties
[12]
Immunogenic
cell death (ICD)
a special form of regulated cell death activated in response to specific
stimuli – ICD inducers (e.g., a number of chemotherapeutic drugs, radio-,
photodynamic, and photothermal therapy regimens, viral load). The key
feature of ICD is gradual release of DAMPs into the extracellular space,
which, together with a number of chemokines and cytokines, act as
adjuvants for antigen-presenting cells (e.g., dendritic cells). Contribution to
immunogenicity is also made by the presence of antigens and neoantigens
expressed by the dying cells. Close interaction between the adjuvant and
antigen properties of ICD culminates in the presentation of antigens on major
histocompatibility complex class I (MHC I) molecules to the CD8
+
T cells.
This process ultimately leads to formation of an immune response and long-
term immunological memory. Since the ICD mechanism is characterized not
only by the release of DAMP patterns, the type of induced cell death and
immunogenic properties must be confirmed not only in vitro but also in
a series of experiments in vivo using syngeneic immunocompetent animals
[13-15]
Types of regulated cell death related to ICD
Immunogenic
apoptosis
an immunogenic apoptosis is characterized by the biochemical mechanism,
for activation of which, in addition to caspase activation, ER stress processes
and generation of reactive oxygen species are required. The mechanism
is selectively blocked by the pan-caspase inhibitor zVAD-fmk (carbobenzoxy-
valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone)
[16, 17]
Necroptosis a caspase-independent form of programmed necrosis with immunogenic
properties; triggered by the suppression of caspase-8 activity, followed by
the sequential activation of the receptor-interacting protein kinases RIPK1
and RIPK3, and then of the pseudokinase MLKL, which forms pores in the
membrane. The mechanism is blocked using specific inhibitors targeting
RIPK1 (e.g., Nec-1s), RIPK3 (e.g., GSK’872), or MLKL (e.g., necrosulfonamide)
[12, 18]
Pyroptosis a regulated form of immunogenic cell death accompanied by inflammation.
Triggered by the assembly of an inflammasome – an intracellular oligomeric
protein complex (e.g., NLRP1, NLRP3, NLRP4 [NOD-like receptors], IRAF,
or AIM2), which promotes activation of caspase-1, or caspases-11, -4, -5.
Under the influence of these proteases, gasdermin D (GSDMD) is cleaved
to form an N-terminal fragment, which embeds in the plasma membrane.
Initially, the cell exhibits morphological signs of apoptosis, but after
membrane damage, the necrosis-like changes occur, manifested primarily
as a sharp increase in membrane permeabilization. Culmination of death
is accompanied by the release of intracellular contents, including DAMPs,
as well as pro-inflammatory cytokines (e.g., IL-1β and IL-18), provoking a
pronounced inflammatory response
[19, 20]
DAMPs IN THE CNS 1825
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
Table 1 (cont.)
Name Characteristics References
Ferroptosis an iron-dependent form of regulated cell death mediated by generation
of reactive oxygen species and lipid peroxidation; triggered by oxidation
of polyunsaturated phosphatidylethanolamines by 15-lipoxygenases against
a background of depleted intracellular glutathione and loss of function
of the antioxidant enzyme GPX4. A decisive factor for ferroptosis is a shift
in the redox balance towards pro-oxidants. The mechanism is blocked
by the inhibitors such as ferrostatin-1 (Fer-1), liproxstatin, vitamin E
(α-tocopherol), and coenzyme Q10
[19, 21]
Cuproptosis a recently discovered type of regulated cell death mediated by accumulation
of divalent copper (Cu
2+
) in mitochondria. Copper, transformed by
ferredoxin (FDX1) into a monovalent state, directly attacks lipoylated
enzymes of the Krebs cycle (DLAT or DLST) or destroys iron-sulfur
proteins. Culmination of death is accompanied by the development
of proteolytic stress and oxidative damage to the cell. The mechanism
is not blocked by the inhibitors of other types of regulated cell death,
such as zVAD-fmk, necrostatin-1, ferrostatin-1, or by the oxidative stress
suppressor N-acetylcysteine. Cuproptosis has not yet been included in the ICD
concept, but data are emerging on its ability to transform the tumor
microenvironment into an immunologically favorable state, contributing
to the development of an adaptive immune response
[22, 23]
a promising strategy for anti-tumor therapy to over-
come resistance and prevent cancer recurrence, as
well as for treatment of other pathologies.
Development of sterile inflammation due to the
DAMP-mediated activation of the innate immune sys-
tem is necessary for tissue regeneration and recovery.
However, it could become excessive and could transi-
tion into chronic inflammation, which is responsible
for pathogenesis of many diseases, including auto-in-
flammatory diseases, metabolic syndrome, cardio-
vascular diseases, neurodegenerative diseases, and
oncological diseases. Release of some DAMPs during
the cell death could have an immunosuppressive ef-
fect  [24]. Emergence of post-translational modifica-
tions of DAMPs could also modulate their functions
in the immune system and provoke the pathology
development  [25].
Thus, deep understanding of whether the im-
mune system recognizes DAMPs as a pathogenic sig-
nal or as a physiological regulatory stimulus is neces-
sary for understanding homeostatic plasticity, causes
of various pathologies, and development of effective
treatment strategies. Such studies are particularly im-
portant in relation to the brain as an immune-privi-
leged organ.
This review focuses on key representatives of
DAMPs – calreticulin (CRT) and high-mobility group
box 1 protein (HMGB1), most often considered in the
context of immunogenic cell death and critically eval-
uates their role in the functioning of central nervous
system (CNS) under normal conditions and during
the development of neuropathologies, particularly
oncological and neurodegenerative processes.
CALRETICULIN
General characteristics. History of the calre-
ticulin (CRT) discovery continues to be a subject
of active scientific discussion. The first mention of
CRT was previously attributed to MacLennan’s labo-
ratory, which in 1974 described a high-affinity cal-
cium-binding protein (HACBP) in a highly purified
preparation of sarcoplasmic reticulum from the rab-
bit skeletal muscle  [26]. In 1984, Waisman and col-
leagues isolated a new calcium-binding protein from
the bovine liver cells and named it calregulin  [27],
which was later characterized in detail (1985) and
partially sequenced (1987)  [28]. In 1989, based on
the nucleotide sequence of mouse cDNA, Koch’s
group determined amino acid sequence of the cal-
cium-binding protein of the endoplasmic reticulum
(ER) lumen, CRP55, and proposed the name calretic-
ulin for it  [29]. Later, it turned out that this protein
is identical to calregulin, and the term calreticulin
became widely accepted. After 50 years, the version
of CRT discovery in 1974 as the HACBP protein was
called into question, giving priority to calregulin.
In a study conducted by Waisman’s laboratory in
2024, evidence was provided that HACBP and calreg-
ulin are distinct proteins  [28]. The analysis showed
that HACBP is a complex of several muscle proteins,
MISHCHENKO et al.1826
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
and its existence as a separate molecule was not con-
firmed  [30].
CRT is a highly conserved calcium-binding pro-
tein with molecular weight of about 46  kDa. CRT con-
sists of 417 amino acids and three domains:
• a globular N-terminal domain, which mediates
interaction with α-integrins and the DNA-binding
site of the steroid receptor;
• a proline-rich P-domain, responsible for creating
a lectin-like chaperone structure;
• a Ca
2+
-binding C-domain, which mediates CRT
interaction with other chaperones in the ER, fol-
lowed by a KDEL motif at the carboxyl terminus,
consisting of four amino acids (Lys-Asp-Glu-Leu),
which ensures retention of the protein in the
ER  [30].
CRT is involved in more than forty intra- and ex-
tracellular processes in mammalian cells. The main
site of CRT localization is ER, where it functions as
a chaperone, in particular, ensuring quality control
of glycoproteins, preventing export of the misfolded
proteins, and supporting their refolding during ER
stress  [31]. In addition, CRT is involved in the reg-
ulation of calcium homeostasis and signaling  [32],
which is of particular importance for CNS cells,
where calcium dynamics play a determining role in
the synaptic transmission and plasticity  [33].
On hippocampal neurons in rats, extracellular
CRT has been shown to co-localize with the NMDA
receptor, which potentially plays a role in modulat-
ing Ca
2+
influx into neurons  [34]. CRT is characterized
by differential expression depending on physiologi-
cal and pathological states under consideration  [35].
In the experimental in  vivo models, it has been
shown that the elevated CRT levels are observed in
the developing brain and retina, while its deficiency
leads to the neural tube closure defects in the embry-
onic period  [36] and development of neurodegenera-
tive processes in the postnatal period [37-39]. In re-
cent in  vitro and in  vivo studies, specific regulation
of CRT expression by the transcription factor ATF6β
has been established. The ATF6β-CRT interaction in-
creases survival of the hippocampal neurons under
ER stress and development of the kainate excitotox-
icity through regulation of the intracellular calcium
homeostasis  [40].
CRT is an important component of the peptide-
loading complex (PLC) in the ER membrane, which
ensures assembly of the MHC I heavy chains with
β
2
-microglobulin, transport of the antigen peptides
from the cytosol into the ERlumen, and their loading
into the antigen-binding groove of MHC I, followed
by the export of assembled complexes via the an-
terograde pathway to the Golgi apparatus and then
to the plasma membrane of the cell [41, 42]. As part
of the PLC complex, CRT maintains a pool of imma-
ture MHC I heavy chains and promotes return of
the suboptimally assembled or dissociated molecules
from the post-ER compartments for re-initiation of
assembly  [43].
CRT has been also found in the nucleus and cy-
toplasm, which indicates multicompartmental nature
of the protein and emphasizes the wide range of its
functions. The nuclear CRT mediates export of a num-
ber of nuclear receptors, including the glucocorticoid
receptor  [44]. The cytoplasmic CRT promotes its acti-
vation by binding to the α-subunit of integrin, which
leads to the short-term increase in cytosolic Ca
2+
con-
centration due to operation of the voltage-dependent
L-type calcium channels and release of Ca
2+
from the
intracellular calcium depots mediated by inositol tris-
phosphate (IP3) [30, 45], and also ensures connection
with the extracellular matrix proteins and the pro-
cess of cell adhesion [30, 46].
“Eat me” signal: role of calreticulin as a DAMP.
With the discovery of the process of CRT exposure on
the surface of the plasma membrane as an “eat me”
signal for phagocytosing cells, the era of considering
it as a DAMP and its role in ICD mechanisms began
[17, 47, 48], which acquired special significance in
the context of anti-tumor immunotherapy, particu-
larly in the therapy of CNS tumors. Since CRT plays
an important role in maintaining intracellular Ca
2+
homeostasis, its role was primarily associated with
immunogenic apoptosis processes (Table  1). However,
today it is understood that the CRT exposure is one of
the three key DAMPs (along with adenosine triphos-
phate [ATP] and HMGB1) considered in the context
of immunogenicity of various types of regulated cell
death (Table  1). In response to an ICD inducer, trans-
port of CRT to the outer surface of the cytoplasmic
membrane usually occurs at an early stage of cell
death due to ER stress, even before the exposure of
phosphatidylserine, which indicates independence of
the process from the nuclear components, DNA dam-
age, and transcriptional changes associated with the
induction of cell death [49, 50]. CRT release is most
often mediated by the depletion of Ca
2+
stores in the
ER. ER stress stimulates the kinase PERK, which, in
turn, phosphorylates the translation initiation factor
eIF2α. This is followed by activation of caspase-8 and
caspase-8-induced proteolysis of the ER protein asso-
ciated with the B-cell receptors 31 (BAP31), as well
as conformational activation of the pro-apoptotic pro-
teins Bax (Bcl-2-associated X-protein) and Bak (Bcl-2
homologous antagonist/killer) [50, 51]. As a result of
these processes, CRT transport to the Golgi appara-
tus occurs, accompanied by the production of reac-
tive oxygen species [50, 51]. Finally, release of the
CRT-containing vesicles to the surface of the plasma
membrane is carried out via the SNARE-dependent
exocytosis (soluble N-ethylmaleimide-sensitive factor
DAMPs IN THE CNS 1827
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
attachment protein receptors)  [50]. Blocking any of
the steps of this complex mechanism with pharmaco-
logical agents (e.g., CRT-blocking antibodies) or genet-
ic interventions (e.g., short interfering RNAs (siRNAs))
nullifies the effect of CRT, reduces immunogenicity of
the cell death process, and, as a consequence, effec-
tiveness of the immune response  [47].
When CRT appears on the surface of the cytoplas-
mic membrane (ecto-CRT), it binds to the low-density
lipoprotein receptor (LRP1, also known as CD91). This
event, together with the secretion of pro-inflamma-
tory cytokines (such as IL-6 and TNF-α) by the pro-
fessional antigen-presenting cells, forms a powerful
phagocytic signal that enhances uptake of antigens
and neoantigens, ensures their subsequent presenta-
tion to the cytotoxic T cells, and, ultimately, leads to
activation of the adaptive immune responses[13,52].
CRT could also move not only to the surface of dy-
ing cells but also of the phagocytes themselves, where
it could act as a phagocytic receptor together with
LRP1  [53]. Itis worth noting that the immunostimula-
tory effects of ecto-CRT are inhibited by co-expression
of the integrin-associated protein CD47, which acts as
a phagocytosis inhibition signal (“don’t eat me” sig-
nal) by binding to the signal regulatory protein SIRPα
on the surface of the antigen-presenting cells [54, 55].
Adelicate balance between the levels of ecto-CRT and
CD47 correlates with the efficiency of binding of dy-
ing cells to phagocytes, and thus with the effective-
ness of the development of the subsequent immune
response and the conducted therapy [55, 56].
Calreticulin as a marker of immunotherapy ef-
ficacy in neurooncology. In carcinogenesis, the au-
tonomous mechanisms of tumor cells responsible for
regulating a balanced functional proteome through
disruption of signaling pathways (e.g., the PERK-eIF2α
pathway) could also contribute to the retention of
CRT inside the cell  [48], or they could secrete mutant
forms of CRT  [57], disrupting signaling between the
dying tumor cells and the immune system cells, thus
reducing effectiveness of ICD. In particular, mutation
in the 9th exon of the crt gene leads to formation of
a modified protein lacking the KDEL motif for reten-
tion in the ER. Appearance of the mutant ecto-CRT
in a number of solid tumors treated with drugs that
induce immunogenic apoptosis (e.g., mitoxantrone,
oxaliplatin) or PD-1 blockade led to suppression of
phagocytosis of the dying tumor cells by dendritic
cells, thereby suppressing the anti-tumor immune
response and effectiveness of immunotherapy  [57].
An increased level of the immunoglobulin-binding
protein (Bip) – a marker of activation of the unfold-
ed protein response – limited the release of DAMP
patterns, including CRT, from the glioma stem cells
when using ionizing radiation regimens that induce
immunogenic apoptosis  [58]. In contrast, inhibiting
Bip facilitated the ionizing radiation-induced ER
stress, which led to generation of DAMP molecules
through phosphorylation of PERK and IRE1-α, further
maturation of dendritic cells, and activation of the
effector T lymphocytes, as well as prevention of the
tumor growth and reduction in the frequency of re-
lapses in the mouse in  vivo model of orthotopic glio-
blastoma  [58].
Release of DAMPs, including CRT, during the
ICD activation could also play a role in the degree
of immunogenicity manifestation and effectiveness of
immunotherapy. It was recently shown that the phar-
macological blockade of CRT or ATP in the whole-cell
lysates of the ferroptotic glioblastoma GL261 cells
significantly reduced effectiveness of the prophylactic
dendritic cell vaccines in the in  vivo orthotopic tumor
model  [59]. Restoring CRT or ATP levels did not lead
to the significant improvement in animal survival,
but it delayed formation of neurological deficits. This
suggests that although individual DAMPs could par-
tially enhance activation of the immune system, they
are insufficient on their own to fully reproduce com-
plex immunogenic profile induced by the ferroptotic
cell death [21, 59].
Thus, deeper understanding of the DAMP signal-
ing pathways, in particular CRT, as well as the rea-
sons for their modulation in carcinogenesis, would
help to establish a productive dialogue between the
induction of ICD and effectiveness of the ICD-based
anti-cancer immunotherapy.
In addition, in some studies, detection of the ec-
to-CRT is considered as an independent prognostic
marker and biomarker of therapy efficacy. For ex-
ample, immunohistochemical analysis of the neuro-
blastoma tissue obtained from 68 patients showed
that the elevated CRT levels positively correlate with
the tumor differentiation, favorable therapy outcome,
and increased survival of the patients at the late stag-
es of the disease  [60]. In the subsequent in  vitro ex-
perimental study by the authors using three different
human neuroblastoma cell lines (SH-SY5Y, SK-N-DZ,
and stNB-V1), it was shown that CRT hyperexpression
suppresses proliferation and enhances differentiation
of the tumor cells by increasing expression of HIF-1α,
followed by activation of the pro-angiogenic factor
VEGF-A  [61]. Blocking the VEGF-A signaling pathway
significantly suppressed expression of the neuronal
markers GAP43, NSE2, NFH, and TrkA, which indi-
cates the key role of VEGF-A in the neuronal differ-
entiation of neuroblastoma cells induced by CRT  [61].
It was also shown that controlling the CRT levels
could affect sensitivity of the human neuroblastoma
cells to radiotherapy and stem cell properties, which
suggests a favorable prognosis for the patient  [62].
In another in  vitro study using two human glioblas-
toma cell lines (U251MG and T98G) and a human
MISHCHENKO et al.1828
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
neuroglioma cell line (H4), it was shown that the
elevated CRT levels enhance sensitivity of the cells
to γ-irradiation. In the case of CRT hyperexpression,
disruption of Ca
2+
homeostasis leads to upregulation
of the protein phosphatase 2Ac alpha (PP2Ac alpha),
which suppresses the Akt signaling pathway, thereby
modulating the radiation-induced apoptosis  [63].
Thus, CRT is an important protein in the process
of immunogenic death of tumor cells. Its transloca-
tion and exposure on the cell surface in response to
ICD induction serves as a signal that attracts phago-
cytes, followed by the development of a persistent
anti-tumor immune response. Understanding the
mechanisms of ecto-CRT exposure regulation and its
interaction with the immune cells is an important di-
rection for the development of new anti-tumor thera-
py strategies aimed at enhancing immunogenicity of
the tumors.
Role of calreticulin in neurodegeneration.
In the context of neurodegeneration, particularly
Alzheimer’s disease (AD), the release of CRT could
act as an alarmin – a danger signal factor released
by the damaged neurons to attract and activate mi-
croglia, as an extracellular chaperone to prevent
β-amyloid (Aβ) aggregation, and as a neuroprotector
against the Aβ-induced neurotoxicity [64, 65]. Thus,
CRT helps maintain Aβ in a soluble state or promotes
its degradation  [66]. In a recent in  vitro study, it was
shown that the increasing concentration of ecto-CRT
to nanomolar concentrations promotes attraction of
microglia, thus activating production of the cytokines
TNF-α, IL-6, IL-1β, and the chemokine CCL2 (C-C motif
ligand 2). In addition to the changes in the morpho-
logical and functional profile of microglia, ecto-CRT
contributed to the blocking of Aβ fibrillization and
modification of its oligomerization, preventing the
Aβ-induced neuronal death in the primary cultures
of cerebral cortex and cerebellum cells of the Wistar
rats (P 3-5)  [64]. Moreover, it has been shown that
CRT could interact with the amyloid precursor pro-
tein (APP) at its γ-secretase cleavage site, as well as
with the components of the γ-secretase complex, pre-
senilin, and nicastrin. Blocking or reducing the CRT
levels, as well as disrupting the CRT binding to APP,
allows APP to directly interact with presenilin and
other components of the γ-secretase complex, which
leads to the enhanced proteolytic cleavage of APP,
increased production and aggregation of Aβ, contrib-
uting to the development of amyloid pathology  [67].
This is consistent with the existing data on the sig-
nificantly lower levels of both CRT mRNA and protein
in the serum of AD patients compared to the healthy
individuals, with the degree of reduction correlating
with progression of clinical manifestations of the dis-
ease  [68]. The reduced CRT expression has also been
observed in the brain cells of AD patients  [37]. This
suggests that the reduced CRT levels in serum could
serve as a diagnostic biomarker for AD.
However, there are alternative data suggesting
a negative role of CRT in the development of AD.
Knockdown of the crt-1 gene reduced locomotion
and resulted in mobility impairments in the Caenor-
habditis elegans (C. elegans) overexpressing the most
toxic human β-amyloid peptide (Aβ1-42). Atthe cellu-
lar level, suppression of the crt-1 gene prevented the
Aβ1-42-induced increase in mitochondrial respiration
and formation of the mitochondrial reactive oxygen
species, as well as it reduced the number and size of
the Aβ1-42 aggregates in the body wall muscle cells
of C. elegans  [69]. Blocking of CRT inhibited the loss
of neurons caused by microglial activation in culture
and in  vivo  [70].
CRT is a common link with pathogenesis of oth-
er neurodegenerative diseases, such as Parkinson’s
disease (PD). Inhibiting CRT increased the death of
neurons in the SH-SY5Y cell line when PD was mod-
elled using 6-hydroxydopamine (6-OHDA). In  vivo, re-
duction in the CRT and ERp57 levels was demonstrat-
ed in the midbrain of rats with the 6-OHDA-induced
parkinsonism  [71]. Similar data were obtained in the
study of the effects of mutation in the crt-1 gene in
C.elegans, which led to the enhanced loss of dopami-
nergic neurons induced by 6-OHDA  [72].
In the context of PD, the data indicating that CRT
regulates the nuclear-cytoplasmic translocation of
α-synuclein in a calcium-dependent manner attract a
great interest  [73]. α-Synuclein plays a critical role in
the onset and progression of PD, forming aggregates
that are the main components of Lewy bodies, char-
acteristic of PD and other neurodegenerative diseases
classified as synucleinopathies. Therefore, disruption
of the CRT-mediated regulation of localization and
nuclear-cytoplasmic translocation of α-synuclein may
be a significant element in the pathogenesis of PD.
These data suggest that the reduced levels of the
components of the CRT/CNX glycoprotein quality con-
trol system may play a role in the neuronal damage in
PD and other neurodegenerative diseases associated
with dysfunction of the ubiquitin-proteasome system.
In a recent study, it was shown that the patients
with secondary-progressive multiple sclerosis have a
significant increase in the CRT levels in cerebrospi-
nal fluid together with other DAMPs, such as annex-
in A1 (ANXA1) and HMGB1, indicating the possibility
of ICD induction and initiation of an adaptive auto-
immune response  [74]. In the mouse model of amy-
otrophic lateral sclerosis (ALS) (SOD1(G93A) line), it
was shown that the CRT levels are reduced two-fold
in the damaged motor neurons. With hemizygous
deletion of SOD1(G93A);crt(+/−), earlier manifestation
of the muscle weakness and muscle denervation was
observed compared to the SOD1(G93A) mice  [39].
DAMPs IN THE CNS 1829
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
Thus, changes in the level of expression and
amount of extracellular CRT could be considered as
a potential biomarker and prognostic criterion for
various brain pathologies. However, further research
is needed to understand the exact role of CRT in the
development of neurodegenerative processes and the
possibility of its use as a therapeutic target, since the
currently available data are ambiguous and partially
contradictory.
HMGB1
General characteristics. High-mobility group
box 1 protein (HMGB1, also known as HMG1 or
amphoterin) belongs to the family of high-mobility
group (HMG) proteins, along with HMGA and HMGN
proteins. This family of highly conserved non-histone
proteins was discovered in 1973 in the calf thymus
chromatin [75, 76]. The human HMGB1 protein has
99% homology with the rodent protein. It consists of
215 amino acids, forming two structurally conserved
DNA-binding domains (HMG-box A and HMG-box B)
connected by a linker, a negatively charged C-terminal
region (acidic tail) enriched with aspartic or glutamic
acid residues, and a short N-terminal fragment  [25].
Extracellular HMG-boxB could exhibit pro-inflamma-
tory properties through interaction with the recep-
tor for advanced glycation end products (RAGE) and
TLR4  [77]. On the other hand, HMG-box A could in-
hibit this pro-inflammatory action by competing with
the full-length HMGB1 or HMG-box B for binding to
the same receptors. The anti-inflammatory function
of HMG-box A is further enhanced when fused with
the C-terminal acidic tail  [78].
HMGB1 is widely represented in the tissues and
organs performing a wide spectrum of functions.
HMGB1 is intensively synthesized during the CNS de-
velopment in the embryonic period, especially in its
early stages  [79], and is closely associated with neuro-
genesis and axonal growth processes. At these stages
of development, HMGB1 is predominantly localized in
the cytoplasm, controlling neurite growth and neuron
maturation  [80]. The HMGB1-CXCL12/CXCR4 signaling
pathway, parallel to the innate immune system, was
discovered in the developing CNS of mice  [81], sug-
gesting that HMGB1 is a key mediator of neuroim-
mune interaction. These same authors showed that
the cells of primary cultures of the cerebral cortex
obtained from the mice with knockout of the Hmgb1
gene did not restore their proliferative activity when
the recombinant HMGB1 was added, which empha-
sizes the important role of the protein in regulating
division of the neuronal precursors  [81].
At the later stages of ontogenesis, the level of
HMGB1 significantly decreases, and in the adult
brain, it is mainly concentrated in the areas with
preserved neurogenesis, such as dentate gyrus of
hippocampus, olfactory bulb, and granular layer of
the cerebellar cortex[79,82]. In recent studies on the
sexually mature CD-1 mice, it was shown that HMGB1
could cross the blood-brain barrier (BBB) in both di-
rections – from the systemic circulation to the CNS
and from the CNS back into the bloodstream, which
potentially suggests its role in maintaining CNS ho-
meostasis and regulating neuroinflammation  [83].
Thus, the role of HMGB1 in the adult brain is not
limited only to regulation of neurogenesis, and the
spectrum of its functions in the CNS under normal
conditions and during the development of pathologies
requires further in-depth study.
Features of HMGB1 localization. Realization of
the HMGB1 functions is largely determined by its lo-
cation in a particular cellular compartment.
In the nucleus, HMGB1 ensures maintenance of
the genome stability, acting as a non-histone chroma-
tin-associated protein and DNA chaperone. In partic-
ular, HMGB1 actively participates in the regulation
of transcription of hundreds of genes and several
transcription factors and is also involved in the DNA
repair systems and recombination processes  [84].
When HMGB1 is translocated to the cytoplasm of
the cell, it binds to Beclin-1 (BECN1), a central protein
that initiates assembly of the Vps34/PI3K-III complex
and formation of autophagosomes, which stimulates
the process of autophagy  [85]. Interaction of HMGB1
with BECN1 also leads to the disruption of its con-
nection with the anti-apoptotic protein Bcl-2, which
suppresses apoptosis. A special role of HMGB1 in
regulating complex interaction between the autoph-
agy and apoptosis has been shown in carcinogenesis.
Increased levels of the cytoplasmic HMGB1 contrib-
ute to the development of resistance of tumor cells to
therapy by enhancing autophagy as a survival mech-
anism [86, 87].
Regulation of the HMGB1 transport between the
nucleus, cytoplasm, and extracellular space is influ-
enced by a number of post-translational modifications.
Particular importance is attached to the oxidative-re-
ductive modifications of three cysteines (C23, C45,
C106), the degree of oxidation of which, occurring due
to the development of stress and generation of reac-
tive oxygen species, regulates release of the protein
into the cytoplasm[25,88] and further into the extra-
cellular space, where HMGB1 could both induce and
suppress the immune response. The state of thiol (-SH)
groups of HMGB1 is influenced by the balance of per-
oxiredoxins Prx1 and Prx2, which catalyze oxidation
of HMGB1  [89], as well as of thioredoxin and glutathi-
one pathway, which inhibit oxidation of HMGB1  [90].
The fully reduced HMGB1, fr-HMGB1, (all three
residues in thiol form) is located in the nuclear space
MISHCHENKO et al.1830
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
and is necessary for structural and regulatory functions
[88, 91]. When released into the extracellular space,
fr-HMGB1 forms a complex with CXCL12 and acts as
a chemoattractant for immune cells  [92]. The partially
oxidized HMGB1, ds-HMGB1, (disulfide C23-C45) has
pronounced pro-inflammatory activity and is respon-
sible for regulating autophagy  [91]. The fully oxidized
HMGB1, ox-HMGB1, is devoid of chemokine and cyto-
kine functions [25, 93].
When released into the extracellular space,
HMGB1 could act as a DAMP, stimulating reactions of
the innate immune system. The extracellular HMGB1
could bind to several PRRs, including the specific re-
ceptor for advanced glycation end products (AGER,
better known as RAGE), TLR2, and TLR4 [94, 95], which
trigger the pro-inflammatory signaling pathways, cy-
tokine and chemokine production, and recruitment of
immune cells. This ability determines the central role
of this protein in initiation of sterile inflammation and
formation of immune response in various patholo-
gies.
Active studying of the functions of extracellular
HMGB1, including its role as a DAMP, began after the
discovery in 1999 of extracellular secretion of HMGB1
by the lipopolysaccharide-induced macrophages, fol-
lowed by the development of inflammation, which
was experimentally confirmed in the in  vivo model
of lethal endotoxemic shock  [96]. Later, it became
known that HMGB1 could be secreted not only from
the immune system cells, such as microglia, macro-
phages, neutrophils, T cells, but also from astrocytes
and neurons  [97]. In a recent study, the release of
HMGB1 in extracellular vesicles by the cortical neu-
rons in response to a single spreading depolarization,
bypassing microglia, was established  [98]. The ves-
icles are absorbed by the perisomatic processes of
astrocytes through a narrow interstitium, initiating
sterile cell-free neuroinflammation. Such neuron-as-
trocyte interaction ensures transmission of the nar-
rowly directed physiological inflammatory signal to
the meninges, informing about transient brain activ-
ity disorders, but without the subsequent develop-
ment of the generalized inflammatory response (e.g.,
absence of microglial activation and degradation of
tissue architecture), characteristic of classical inflam-
mation  [98].
Active and passive release of HMGB1 into ex-
tracellular space. Release of HMGB1 into the extra-
cellular space occurs in two main ways: active secre-
tion or passive release.
Unlike other soluble secreted proteins, absence of
a leader sequence in HMGB1 does not allow it to be
actively secreted via the traditional ER–Golgi secre-
tory pathway  [99]. To date, the most widely accept-
ed model is that active release of HMGB1 occurs by
packaging the protein into the intracellular vesicles
(e.g., lysosomes) followed by their fusion with the
plasma membrane and release into the extracellular
space [25, 76]. The mechanism includes three main
stages:
• acetylation of HMGB1 and its subsequent chro-
mosomal dissociation;
• export of HMGB1 from the nucleus to the cytosol
using the transport protein exportin1 (XPO1, also
known as CRM1);
• aggregation of HMGB1 in lysosomes and release
outward through lysosomal exocytosis [76, 100].
A number of studies note that the mechanism
of active HMGB1 secretion could be regulated by
post-translational modifications (ADP-ribosylation,
phosphorylation, methylation, acetylation, glycosyla-
tion), level of reactive oxygen and nitrogen species,
ionic homeostasis (primarily Ca
2+
), activation of tran-
scription factors and inflammasomes, as well as by
the features of intercellular interactions  [25,  76]. Deep
understanding of this regulatory network opens op-
portunities for the development of targeted therapy
aimed at selective inhibition of the pathological re-
lease of HMGB1 without disruption of its physiologi-
cal functions.
Passive release of HMGB1 is detected during the
uncontrolled cell death (necrosis) and autophagy-me-
diated cell death, as well as at the late stages of the
regulated cell death pathways, including apoptosis,
necroptosis, pyroptosis, ferroptosis (Fig.  2).
HMGB1 released during necrotic cell death is
predominantly in the disulfide or partially oxi-
dized form; it enhances pro-inflammatory reactions
through the TLR4 and RAGE signaling pathways. This
is of particular importance as an early marker of in-
flammation in the CNS pathologies such as ischemic
stroke, traumatic brain injuries, and active neurode-
generative processes, where massive cell death leads
to rapid accumulation of HMGB1 and development of
sterile neuroinflammation.
At the late stage of apoptosis (Table  1), passive
release of HMGB1 from dying cells occurs in a
caspase-3- dependent manner  [101], followed by the
development of ICD  [94], or immunological tolerance
in the case of presence of the oxidized form of the
protein [102] (Fig.  2).
In the case of necroptosis (Table  1), development
of the RIPK1-dependent inflammation occurs, mediat-
ed by the HMGB1-TLR4 signaling pathway. The TLR4
signaling pathway is involved in the secretion of
HMGB1 from macrophages through the mechanism
dependent on interleukin-1 receptor-associated ki-
nase 4 (IRAK4) [18, 103]. The release of HMGB1, due
to induction of the RIPK3-MLKL-dependent necropto-
sis in the hippocampus, contributes to the develop-
ment of neuroinflammation and formation of the de-
pression-like behavior in mice  [104]. Inhibiting RIPK1
DAMPs IN THE CNS 1831
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
Fig.  2. Key mechanisms of passive HMGB1 release into the extracellular space. Passive release of HMGB1 occurs during
uncontrolled cell death (necrosis), as well as at the late stages of regulated cell death pathways, including apoptosis, necro-
ptosis, pyroptosis, ferroptosis, cuproptosis. Redox status of HMGB1 determines the pathway of immune response activation:
development of sterile inflammation, induction of ICD, or immunological tolerance. In the case of ICD induction, HMGB1
released into the extracellular space, together with other danger molecules, forms a DAMP pattern that acts as a powerful
adjuvant for the recruitment and maturation of the antigen-presenting cells (e.g., dendritic cells), followed by formation of
an adaptive T-cell anti-tumor immune response.
and/or RIPK3, or depleting the pseudokinase MLKL,
blocks the release of HMGB1 in various inflammatory
conditions  [105] (Fig.  2).
Unlike apoptosis and necroptosis, HMGB1 re-
leased during pyroptosis (Table  1) via the inflam-
masome pathway [106, 107] is in the hyperacetylat-
ed state and at the final stages of death is present
in the disulfide form  [108]. The JAK/STAT1 signaling
pathway ensures hyperacetylation of HMGB1 and its
cytoplasmic accumulation for its subsequent release
into the extracellular space from the immune cells in-
duced by lipopolysaccharide  [109]. In a recent study,
it was shown that the release of HMGB1 during in-
flammasome activation is GSDMD-dependent, but the
release occurs not through the GSDMD pores, but due
to membrane rupture  [110]. Caspase 8 (Casp8) could
also contribute to the GSDMD-dependent pyroptosis
with HMGB1 release during the infection develop-
ment  [111] (Fig.  2).
Currently, it is known that the release of HMGB1
from ferroptotic cells (Table  1) occurs via an autoph-
agy-dependent mechanism. It was shown as a result
of testing of a wide range of ferroptosis inducers in
both tumor and healthy cells that the autophagy-me-
diated inhibition of histone deacetylase (HDAC) leads
to the HMGB1 acetylation, its release from the dying
cells, followed by the development of the RAGE-de-
pendent inflammation in macrophages  [112] (Fig.  2).
Thus, passive release of HMGB1 into extracel-
lular space could occur both via immunogenic and
non-immunogenic pathways.
Role of HMGB1 in neurooncology. In the con-
text of oncological diseases, particularly brain tu-
mors, HMGB1 could play a dual role.
On the one hand, HMGB1 is involved in the tu-
mor invasion and metastasis processes and is consid-
ered by a number of researchers as a therapeutic tar-
get. For example, the use of temozolomide increases
the level of expression of HMGB1 in the glioblastoma
cells obtained from the patient biopsies and promotes
its further release into the tumor microenvironment.
There, through activation of the TLR2/NEAT1/Wnt sig-
naling pathway, HMGB1 enhances production of the
cancer stem cells, ensuring development of resistance
to the conducted therapy  [113]. The authors consid-
er combination of temozolomide with an HMGB1
MISHCHENKO et al.1832
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
inhibitor as a new strategy to overcome resistance
and improve quality of the conducted therapy. In the
animal models, blocking the HMGB1–RAGE interac-
tion contributed to reduction in the growth and me-
tastasis of both grafted and spontaneously develop-
ing tumors  [37]. The use of neutralizing anti-HMGB1
antibodies contributed to the reduction in the vessel
permeability and edema in the microenvironment of
orthotopic glioma, increasing survival of the mice re-
ceiving oncolytic viral therapy  [114].
The main mechanism by which the extracellular
HMGB1 acts as a DAMP and is an important compo-
nent of immunogenicity of the cell death lies in acti-
vation of the myeloid differentiation primary response
protein (MYD88) of the TLR4 pathway and its adapter
on the surface of antigen-presenting cells [94, 115].
This activation underlies processing and presentation
of antigens from the dying cells, a necessary compo-
nent of the further development of adaptive immune
response. Desensitization of the tumor microenviron-
ment to the TLR4 receptor or oxidation of HMGB1
under the action of ROS could lead to inactivation
of TLR4, suppressing phagocytic activity of the anti-
gen-presenting cells and development of immune tol-
erance  [116]. It has also been shown that the release
of HMGB1 from the dying glioma cells due to effects
of the combined therapy with an adenoviral vector
and radiochemotherapy based on temozolomide con-
tributes to infiltration of dendritic cells and regression
of the TLR-2-dependent brain tumors in  vivo  [117].
In recent studies, it has been established that
the release of HMGB1 in combination with other key
DAMPs during activation of cuproptosis (Table  1) in
the glioblastoma cells demonstrates a synergistic an-
ti-tumor effect in combination with temozolomide, as
well as contributes to the development of an adaptive
immune response, including ensuring maturation of
the dendritic cells and remodeling of the tumor mi-
croenvironment, stimulating infiltration of the CD8
+
T cells and reducing intensity of the tumor growth
[118, 119] (Fig.  2).
However, the release of HMGB1 should be at-
tributed rather to the general signs of cell death
(the fact of membrane permeabilization) than to the
specific markers of ICD [13, 120]. For example, un-
like CRT and ATP, pharmacological blockade of the
HMGB1-TLR4 pathway in the whole-cell ferroptotic ly-
sates of the glioblastoma GL261 cells did not have a
significant effect on the effectiveness of prophylactic
dendritic cell vaccines in the orthotopic tumor in  vivo
model  [59]. However, blocking all three DAMPs in the
ferroptotic lysates of the glioblastoma cells led to the
maximum suppression of immunogenicity of the den-
dritic cell vaccines  [59].
Thus, for complete characterization of immuno-
genicity of the cell death process, it is worth consid-
ering dynamics of the release of the entire DAMP pat-
tern, including the release of CRT and ATP. According
to the “gold standard” for defining ICD, it is also nec-
essary to conduct studies to establish phenotypic sta-
tus and phagocytic activity of the antigen-presenting
cells in the presence of dying/dead cells in  vitro and
to assess effectiveness of prophylactic vaccination
with dying cells in the in  vivo tumor models using
syngeneic immunocompetent animals [13-15].
HMGB1 in neurodegenerative diseases. Hyper-
production and release of HMGB1 into the extracellu-
lar space is one of the important pathogenetic mech-
anisms in neurodegenerative diseases. Many factors
associated with neurodegeneration could provoke the
release of HMGB1, such as oxidative stress, hypoxia,
inflammation, as well as traumatic injuries and vi-
ral infections [106, 121]. Disruption of the regulation
of expression and activity of peroxiredoxins and, in
general, of the oxidative-reductive balance contrib-
utes to the development of chronic HMGB1-induced
low-level inflammation and is observed in almost all
neurodegenerative diseases  [122].
The HMGB1-mediated activation of glial cells,
primarily microglia and astrocytes, in a neurotoxic
manner leads to the excessive production of pro-in-
flammatory cytokines, chemokines, reactive oxygen
species (including superoxide anions, hydrogen per-
oxide, hydroxyl radicals), and nitrogen species (NO),
as well as proteolytic enzymes. This disrupts synaptic
homeostasis, neuronal metabolism, leads to increase
in the BBB permeability, and ultimately contributes
significantly to the CNS pathology, promoting neuro-
nal damage and accelerating neurodegenerative pro-
cesses  [123]. Moreover, neurodegenerative changes in
AD and PD, including formation of protein aggregates
of Aβ and α-synuclein, could, in turn, enhance neu-
roinflammation and additionally activate glial cells.
Thus, a loop of positive feedback is formed, creating
a self-reproducing and self-enhancing inflammatory
environment  [124]. Formation of such inflammatory
environment is a universal feature of all neurodegen-
erative diseases.
In addition to the direct interaction with recep-
tors, HMGB1 could enhance inflammatory processes
by forming heterocomplexes with other DAMPs and
pro-inflammatory molecules  [125], including cyto-
kines and chemokines [126-128], and mitochondrial
DNA  [129]. Formation of such complexes multiplies
the inflammatory signal through the TLR receptors
(including TLR3, TLR7, and TLR9), NF-κB, and com-
plement pathways, leading to the enhanced activation
of microglia with the neurotoxic M1 phenotype and
disruption of the BBB integrity.
The BBB regulates transport of various molecules
and ions from the bloodstream to nerve cells, pre-
venting entry of pathogens and neurotoxins  [121].
DAMPs IN THE CNS 1833
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
Fig.  3. Signaling pathways of HMGB1 in neurodegenerative processes. HMGB1 could interact with extracellular peptide
aggregates (β-amyloid in AD or α-synuclein in PD), which leads to disruption of clearance of these proteins by microglia
and their accumulation in the extracellular space. This causes synaptic dysfunction, development of neuroinflammation,
and oxidative stress. Binding of HMGB1 to RAGE and TLR receptors (including TLR2, TLR4, TLR5, TLR9) induces NF-κB-me-
diated neuroinflammation, leading to increase in the production of pro-inflammatory cytokines, including TNF-α, IL-6, and
IL-1β. In response to production of pro-inflammatory cytokines, activation of microglia and astrocytes with neurotoxic
phenotype occurs, leading to formation of a vicious cycle of neuroinflammation and oxidative stress. Activation of the
RAGE/TLR4-ERK1/2, RAGE/CaMKK-β-AMPK, and RAGE/GSK-3β pathways enhances production and accumulation of Aβ and
abnormal hyperphosphorylation of tau protein. In addition, activation of the HMGB1/RAGE and HMGB1/TLR pathways
disrupt integrity of the blood-brain barrier (BBB), which, in turn, enhances neuroinflammation. The resulting multiple
positive feedback loops enhance neurodegenerative processes and lead to the death of both neurons and glial cells.
It should be noted that permeability of the BBB sig-
nificantly increases during the development of neu-
rodegenerative processes, which leads to disruptions
in the homeostasis of the brain intercellular environ-
ment  [130]. HMGB1 could increase permeability of
the BBB by activating the TLR4 pathway and under-
lying signaling pathways NF-κB, Erk1/2, and Akt in
the endothelial cells in a paracrine manner, as shown
both in in  vivo and in  vitro models  [131]. An import-
ant role in the disruption of the BBB permeability is
played by degradation of the tight junction proteins,
such as zonula occludens-1 (ZO-1) [132,  133]. The use
of antibodies against HMGB1 reduces severity of
brain edema and decreases permeability of the BBB
in various pathologies, in PD in particular.
Interaction of HMGB1 with the protein aggre-
gates formed in AD and PD, which disrupt normal
functioning of the neurons and lead to their death,
is of particular interest in the context of the devel-
opment of neurodegeneration and inflammatory pro-
cesses. It has been shown that HMGB1, by binding to
the Aβ42 peptide – one of the key factors provoking
AD – inhibits its phagocytosis by macrophages, as
well as by microglial cells, and reduces clearance of
the Aβ42 peptides introduced into the rat brain  [134].
In the brain and serum of the AD patients, increase
in the HMGB1 levels has been observed, which is
probably one of the important causes of impaired
clearance of amyloid peptides [133-135]. In addition,
it has been shown that in the brain tissues of AD pa-
tients, HMGB1 accumulates in the Aβ plaques and in
the surrounding microglial cells. In turn, both Aβ42
oligomers and pathological tau oligomers could acti-
vate the secretion of HMGB1 by microglia, sustain-
ing the vicious cycle of neuroinflammation develop-
ment  [136].
The second mechanism by which HMGB1 stim-
ulates production of the Aβ peptides is activation
MISHCHENKO et al.1834
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
of the RAGE receptor, which is expressed in microg-
lial cells and neurons, and in AD, its expression is
increased  [137]. Hyperexpression of RAGE by the
microglial cells enhances production and accumu-
lation of Aβ42 in the hippocampus and cortex of
the transgenic mice, increased severity of neuroin-
flammation, and contributed to the loss of cholin-
ergic neurons  [138]. The influence of RAGE on the
Aβ42 production is associated with enhancement of
amyloidogenic processing of the Aβ precursor by
increasing activity of the β- and γ-secretases and
GSK3β kinase  [139]. A scheme summarizing signal-
ing pathways activated by HMGB1 during the devel-
opment of neurodegenerative processes is presented
in Fig.  3.
In the postmortem studies of midbrain tissues,
as well as of cerebrospinal fluid and serum of the
PD patients, the elevated levels of HMGB1 were de-
tected. It was established that the HMGB1 protein
was located mainly in the nucleus of the cells in the
healthy individuals and in the cytoplasm of the PD
patients, which may indicate involvement of HMGB1
translocation in pathogenesis of the disease  [140].
HMGB1 could bind to the aggregated α-synuclein and
be present in Lewy bodies containing α-synuclein fil-
aments isolated from the brain tissue  [141]. It has
been shown that the extracellular HMGB1-mediated
activation of RAGE and TLR4 signaling pathways in
PD accelerates the death of dopaminergic neurons
and enhances inflammation in the substantia nigra,
with excessive production and release of HMGB1
occurring already at the early stages of the dis-
ease  [142]. It is worth noting that the endogenous in-
tracellular cytoplasmic HMGB1, on the contrary, pro-
motes degradation of α-synuclein through autophagy
in the PC12 neuroblastoma cell line  [143].
In the ALS patients, increased serum levels of
the anti-HMGB1 autoantibodies were observed com-
pared to the healthy individuals of the corresponding
age  [144]. At the same time, in the ALS patients and
in the mouse models, nucleocytoplasmic translocation
of HMGB1 was observed in the reactive astrocytes
and microglia[145,146]. Thus, HMGB1 could serve as
a biomarker for diagnosis and clinical assessment of
ALS. In ALS, as in other forms of neurodegeneration,
HMGB1 could initiate a positive feedback loop, which,
as shown both in humans and in animal models, ex-
acerbates neuroinflammatory and neurodegenerative
processes [145, 147].
In autoimmune neurodegenerative diseases,
such as multiple sclerosis, HMGB1 activates the
TLR4/NF-κB signaling pathway and induces pyropto-
sis in the microglial and other cells [148,  149]. The
HMGB1-induced inflammation, in turn, contributes to
demyelination. It has been suggested that increase in
the HMGB1 levels in the cerebrospinal fluid, but not
in serum, could be considered as a prognostic bio-
marker in multiple sclerosis  [149].
Thus, HMGB1 plays an important role in the de-
velopment of neurodegeneration, primarily through
induction of neuroinflammatory processes, and,
therefore, could be considered as a target for the
therapy of neurodegenerative diseases. The main tar-
geted approaches associated with HMGB1 include the
use of neutralizing antibodies, low-molecular-weight
antagonists (e.g., glycyrrhizin and ethyl pyruvate),
competitive peptide antagonist BoxA, which binds to
HMGB1 receptors and blocks signaling, as well as an-
ti-inflammatory compounds of plant origin and cho-
linergic agonists  [121]. Targeting HMGB1 has shown
high efficacy in the experimental and preclinical
models of AD, PD, ALS, and several other pathologies
[121,150], but clinical validation is practically absent.
This direction requires further in-depth study.
CONCLUSION
Contrary to the classical paradigm of brain im-
mune privilege, which has its own immune cells –
microglia (Fig.  1) – and lacks peripheral immune
cells, evidence has been accumulated of close in-
teraction between the CNS and the immune system.
The key links in this dialogue are DAMP molecules,
which are widely represented in the brain, and their
receptors are actively expressed not only by microg-
lia, but also by astrocytes, neurons, endothelial cells,
and infiltrating peripheral immune cells in the cases
of vessel damage or BBB destabilization.
The key DAMPs reviewed in this article – CRT
and HMGB1 – play multiple roles in the CNS. Under
physiological conditions, they ensure normal function-
ing of the brain, including acting as necessary effec-
tors of neurogenesis and homeostatic plasticity. When
stress or a pathological stimulus (a “danger signal”)
occurs, these molecules act as mediators between the
dying cells and immune system, determining the path-
ways of immune response development: activation of
sterile inflammation, induction of ICD, or, conversely,
development of immunological tolerance.
Dysregulation, post-translational modifications,
or excessive release of DAMPs into the tumor micro-
environment or during neurodegenerative processes
triggers a cascade of pro-inflammatory signals, exac-
erbating chronic neuroinflammation, disrupting integ-
rity of the BBB, and forming resistance to therapy.
Deep understanding of the mechanisms of confor-
mational transformations of DAMPs, their concentra-
tion and kinetics of release, as well as features of
their interaction with other DAMPs and formation
of a complex pattern of danger molecules, becomes
the key to controlling immune reactions in the CNS.
DAMPs IN THE CNS 1835
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
In this regard, detection of ecto-CRT and HMGB1 in
the biological fluids or brain tissues could become
an important prognostic tool, and regulation of the
DAMP signaling pathways opens promising approach-
es for overcoming tumor resistance or inhibiting pro-
gressive neurodegenerative changes in the brain. The
key challenge for future research is development of
the strategies that allow selective modulation of the
signaling pathways of CRT and HMGB1, while pre-
serving their physiological functions. This would en-
able effective translation of the knowledge about the
DAMPs into the safe therapy methods aimed at restor-
ing homeostasis and immune surveillance in the CNS.
Abbreviations
Aβ β-amyloid
AD Alzheimer’s disease
ALS amyotrophic lateral sclerosis
ATP adenosine triphosphate
BBB blood-brain barrier
CNS central nervous system
CRT calreticulin
DAMP damage-associated molecular
pattern
ER endoplasmic reticulum
HMGB1 high-mobility group box 1
ICD immunogenic cell death
IL interleukin
MHC I major histocompatibility complex
class I
PAMP pathogen-associated molecular pattern
PRR pattern-recognition receptor
RAGE (AGER) receptor for advanced glycation end
products
TLR Toll-like receptor
Acknowledgments
The authors express their deep gratitude to Prof.
Dmitri V. Krysko, whose invaluable scientific contri-
bution, scientific vision, and mentorship largely de-
termined the content of this work.
Contributions
T.  A.  Mishchenko, D.  V.  Krysko, and M.  V.  Vedunova:
concept and supervision of the work, writing and
editing of the article text. E.  V.  Mitroshina: literature
search and analysis, writing and editing of the article
text. S.  S.  Kulikov, A.  A.  Grechukhina, and O.  J.  Olajide:
literature search and analysis, writing of the text,
preparation of graphical material.
Funding
This work was carried out within the framework of
the state assignment of the Ministry of Science and
Higher Education of the Russian Federation (project
no. FSWR-2026-0015).
Ethics approval and consent to participate
This work does not contain any studies involving hu-
man and animal subjects.
Conflict of interest
The authors of this work declare that they have no
conflicts of interest.
REFERENCES
1. Janeway, C. A., Jr. (1989) Approaching the asymptote? Evolution and revolution in immunology, Cold Spring
Harb. Symp. Quant. Biol., 54, 1-13, https://doi.org/10.1101/sqb.1989.054.01.003.
2. Matzinger, P. (1994) Tolerance, danger, and the extended family, Annu. Rev. Immunol., 12, 991-1045, https://
doi.org/10.1146/annurev.iy.12.040194.005015.
3. Matzinger, P. (2002) The danger model: a renewed sense of self, Science, 296, 301-305, https://doi.org/10.1126/
science.1071059.
4. Land, W. (2003) Allograft injury mediated by reactive oxygen species: from conserved proteins of Drosophila
to acute and chronic rejection of human transplants. Part III: interaction of (oxidative) stress-induced heat
shock proteins with toll-like receptor-bearing cells of innate immunity and its consequences for the devel-
opment of acute and chronic allograft rejection, Transplantat. Rev., 17, 67-86, https://doi.org/10.1016/S0955-
470X(02)00009-5.
5. Seong, S. Y., et al. (2004) Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate
immune responses, Nat. Rev. Immunol., 4, 469-478, https://doi.org/10.1038/nri1372.
6. Galluzzi, L., et al. (2024) Targeting immunogenic cell stress and death for cancer therapy, Nat. Rev. Drug Discov.,
23, 445-460, https://doi.org/10.1038/s41573-024-00920-9.
7. Cao, X. (2016) Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and dis-
ease, Nat. Rev. Immunol., 16, 35-50, https://doi.org/10.1038/nri.2015.8.
8. Ford, J. W., et al. (2009) TREM and TREM-like receptors in inflammation and disease, Curr. Opin. Immunol., 21,
38-46, https://doi.org/10.1016/j.coi.2009.01.009.
9. Hudson, B. I., et al. (2018) Targeting RAGE signaling in inflammatory disease, Annu. Rev. Med., 69, 349-364,
https://doi.org/10.1146/annurev-med-041316-085215.
MISHCHENKO et al.1836
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
10. Gong, T., et al. (2020) DAMP-sensing receptors in sterile inflammation and inflammatory diseases, Nat. Rev.
Immunol., 20, 95-112, https://doi.org/10.1038/s41577-019-0215-7.
11. Galluzzi, L., et al. (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee
on Cell Death 2018, Cell Death Differ., 25, 486-541, https://doi.org/10.1038/s41418-017-0012-4.
12. Aaes, T. L., et al. (2016) Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity, Cell
Rep., 15, 274-287, https://doi.org/10.1016/j.celrep.2016.03.037.
13. Galluzzi, L., et al. (2020) Consensus guidelines for the definition, detection and interpretation of immunogenic
cell death, J. Immunother. Cancer, 8, e000337, https://doi.org/10.1136/jitc-2019-000337.
14. Humeau, J., et al. (2019) Gold Standard assessment of immunogenic cell death in oncological mouse models,
Methods Mol. Biol., 1884, 297-315, https://doi.org/10.1007/978-1-4939-8885-3_21.
15. Mishchenko, T. A., et al. (2024) Gold standard assessment of immunogenic cell death induced by photodynamic
therapy: from in vitro to tumor mouse models and anti-cancer vaccination strategies, Methods Cell Biol., 183,
203-264, https://doi.org/10.1016/bs.mcb.2023.05.003.
16. Casares, N., et al. (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death, J. Exp.
Med., 202, 1691-1701, https://doi.org/10.1084/jem.20050915.
17. Krysko, D. V., et al. (2012) Immunogenic cell death and DAMPs in cancer therapy, Nat. Rev. Cancer, 12, 860-875,
https://doi.org/10.1038/nrc3380.
18. Kaczmarek, A., et al. (2013) Necroptosis: the release of damage-associated molecular patterns and its physiolog-
ical relevance, Immunity, 38, 209-223, https://doi.org/10.1016/j.immuni.2013.02.003.
19. Hadian, K., et al. (2023) The therapeutic potential of targeting regulated non-apoptotic cell death, Nat. Rev. Drug
Discov., 22, 723-742, https://doi.org/10.1038/s41573-023-00749-8.
20. Huang, C., et al. (2025) Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical per-
spectives, Mol. Cancer, 24, 131, https://doi.org/10.1186/s12943-025-02344-4.
21. Catanzaro, E., et al. (2024) Immunogenicity of ferroptosis in cancer: a matter of context? Trends Cancer, 10,
407-416, https://doi.org/10.1016/j.trecan.2024.01.013.
22. Li, J., et al. (2025) Immunogenic cuproptosis in cancer immunotherapy via an in situ cuproptosis-inducing sys-
tem, Biomaterials, 319, 123201, https://doi.org/10.1016/j.biomaterials.2025.123201.
23. Tsvetkov, P., et al. (2022) Copper induces cell death by targeting lipoylated TCA cycle proteins, Science, 375,
1254-1261, https://doi.org/10.1126/science.abf0529.
24. Hayashi, K., et al. (2021) Inhibitory DAMPs in immunogenic cell death and its clinical implications, Cell Stress,
5, 52-54, https://doi.org/10.15698/cst2021.04.247.
25. Chen, R., et al. (2022) The mechanism of HMGB1 secretion and release, Exp Mol Med, 54, 91-102, https://
doi.org/10.1038/s12276-022-00736-w.
26. Ostwald, T. J., et al. (1974) Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulum,
J.Biol. Chem., 249, 974-979, https://doi.org/10.1016/S0021-9258(19)43026-3.
27. Waisman, D. M., et al. (1984) Identification of a novel hepatic calcium binding protein, Biochem. Biophys. Res.
Commun., 119, 440-446, https://doi.org/10.1016/s0006-291x(84)80268-5.
28. Okura, G.C., etal. (2024) Calreticulin-enigmatic discovery, Biomolecules, 14, 866, https://doi.org/10.3390/biom14070866.
29. Smith, M. J., et al. (1989) Multiple zones in the sequence of calreticulin (CRP55, calregulin, HACBP), a major
calcium binding ER/SR protein, EMBO J., 8, 3581-3586, https://doi.org/10.1002/j.1460-2075.1989.tb08530.x.
30. Okura, G. C., et al. (2025) Calreticulin-from the endoplasmic reticulum to the plasma membrane-adventures of
a wandering protein, Cancers (Basel), 17, 288, https://doi.org/10.3390/cancers17020288.
31. Gelebart, P., et al. (2005) Calreticulin, a Ca
2+
-binding chaperone of the endoplasmic reticulum, Int. J. Biochem.
Cell Biol., 37, 260-266, https://doi.org/10.1016/j.biocel.2004.02.030.
32. Michalak, M. (2024) Calreticulin: endoplasmic reticulum Ca
2+
gatekeeper, J. Cell Mol. Med., 28, e17839, https://
doi.org/10.1111/jcmm.17839.
33. Pikor, D., et al. (2024) Calcium ions in the physiology and pathology of the central nervous system, Int. J. Mol.
Sci., 25, 13133, https://doi.org/10.3390/ijms252313133.
34. Hossain, M. A., et al. (2000) Evidence of [Ca(2+)]i elevation by anti-calreticulin immunoreactive protein in neu-
rons, Neurosci Res, 36, 285-290, https://doi.org/10.1016/s0168-0102(99)00130-3.
35. Qiu, Y., et al. (2009) Transcriptional control of the calreticulin gene in health and disease, Int. J. Biochem. Cell
Biol., 41, 531-538, https://doi.org/10.1016/j.biocel.2008.06.020.
36. Rauch, F., et al. (2000) Heart, brain, and body wall defects in mice lacking calreticulin, Exp. Cell Res., 256, 105-
111, https://doi.org/10.1006/excr.2000.4818.
37. Taguchi, J., et al. (2000) Different expression of calreticulin and immunoglobulin binding protein in Alzheimer’s
disease brain, Acta Neuropathol., 100, 153-160, https://doi.org/10.1007/s004019900165.
DAMPs IN THE CNS 1837
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
38. Bernard-Marissal, N., et al. (2012) Reduced calreticulin levels link endoplasmic reticulum stress and Fas-trig-
gered cell death in motoneurons vulnerable to ALS, J. Neurosci., 32, 4901-4912, https://doi.org/10.1523/jneurosci.
5431-11.2012.
39. Bernard-Marissal, N., et al. (2015) Calreticulin levels determine onset of early muscle denervation by fast mo-
toneurons of ALS model mice, Neurobiol. Dis., 73, 130-136, https://doi.org/10.1016/j.nbd.2014.09.009.
40. Nguyen, D. T., et al. (2021) The ATF6β-calreticulin axis promotes neuronal survival under endoplasmic reticulum
stress and excitotoxicity, Sci. Rep., 11, 13086, https://doi.org/10.1038/s41598-021-92529-w.
41. Kotsias, F., et al. (2019) Antigen processing and presentation, Int. Rev. Cell Mol. Biol., 348, 69-121, https://
doi.org/10.1016/bs.ircmb.2019.07.005.
42. Blees, A., et al. (2017) Structure of the human MHC-I peptide-loading complex, Nature, 551, 525-528, https://
doi.org/10.1038/nature24627.
43. Howe, C., et al. (2009) Calreticulin-dependent recycling in the early secretory pathway mediates optimal peptide
loading of MHC class I molecules, EMBO J., 28, 3730-3744, https://doi.org/10.1038/emboj.2009.296.
44. Holaska, J. M., et al. (2001) Calreticulin Is a receptor for nuclear export, J. Cell Biol., 152, 127-140, https://
doi.org/10.1083/jcb.152.1.127.
45. Coppolino, M. G., et al. (1999) Ligand-specific, transient interaction between integrins and calreticulin during
cell adhesion to extracellular matrix proteins is dependent upon phosphorylation/dephosphorylation events,
Biochem. J., 340, 41-50, https://doi.org/10.1042/bj3400041.
46. Coppolino, M. G., et al. (1997) Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion,
Nature, 386, 843-847, https://doi.org/10.1038/386843a0.
47. Obeid, M., et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death, Nat. Med., 13,
54-61, https://doi.org/10.1038/nm1523.
48. Fucikova, J., et al. (2021) Calreticulin and cancer, Cell Res., 31, 5-16, https://doi.org/10.1038/s41422-020-0383-9.
49. Panaretakis, T., et al. (2008) The co-translocation of ERp57 and calreticulin determines the immunogenicity of
cell death, Cell Death Differ., 15, 1499-1509, https://doi.org/10.1038/cdd.2008.67.
50. Panaretakis, T., et al. (2009) Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death,
EMBO J., 28, 578-590, https://doi.org/10.1038/emboj.2009.1.
51. Garg, A. D., et al. (2012) A novel pathway combining calreticulin exposure and ATP secretion in immunogenic
cancer cell death, EMBO J., 31, 1062-1079, https://doi.org/10.1038/emboj.2011.497.
52. Zhao, L., et al. (2022) Interference of immunogenic chemotherapy by artificially controlled calreticulin secretion
from tumor cells, Methods Cell Biol., 172, 99-114, https://doi.org/10.1016/bs.mcb.2021.12.027.
53. Feng, M., et al. (2015) Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and
Btk, Proc. Natl. Acad. Sci. USA, 112, 2145-2150, https://doi.org/10.1073/pnas.1424907112.
54. Oldenborg, P. A., et al. (2001) CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and comple-
ment receptor-mediated phagocytosis, J. Exp. Med., 193, 855-862, https://doi.org/10.1084/jem.193.7.855.
55. Du, R., et al. (2024) Glioblastoma phagocytic cell death: balancing the opportunities for therapeutic manipulation,
Cells, 13, 823, https://doi.org/10.3390/cells13100823.
56. Feng, M., et al. (2019) Phagocytosis checkpoints as new targets for cancer immunotherapy, Nat. Rev. Cancer, 19,
568-586, https://doi.org/10.1038/s41568-019-0183-z.
57. Liu, P., et al. (2020) Immunosuppression by mutated calreticulin released from malignant cells, Mol. Cell, 77,
748-760.e749, https://doi.org/10.1016/j.molcel.2019.11.004.
58. Yang, W., et al. (2020) Bip inhibition in glioma stem cells promotes radiation-induced immunogenic cell death,
Cell Death Dis., 11, 786, https://doi.org/10.1038/s41419-020-03000-z.
59. Saviuk, M., et al. (2026) Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy, Nat. Commun., 17,
6158, https://doi.org/10.1038/s41467-026-72737-6.
60. Hsu, W. M., et al. (2005) Calreticulin expression in neuroblastoma – a novel independent prognostic factor, Ann.
Oncol., 16, 314-321, https://doi.org/10.1093/annonc/mdi062.
61. Weng, W. C., et al. (2015) Calreticulin regulates VEGF-A in neuroblastoma cells, Mol. Neurobiol., 52, 758-770,
https://doi.org/10.1007/s12035-014-8901-8.
62. Chen, C. J., et al. (2023) Calreticulin expression controls cellular redox, stemness, and radiosensitivity to func-
tion as a novel adjuvant for radiotherapy in neuroblastoma, Oxid. Med. Cell Longev., 2023, 8753309, https://
doi.org/10.1155/2023/8753309.
63. Okunaga, T., et al. (2006) Calreticulin, a molecular chaperone in the endoplasmic reticulum, modulates radiosensi-
tivity of human glioblastoma U251MG cells, Cancer Res., 66, 8662-8671, https://doi.org/10.1158/0008-5472.Can-05-4256.
64. Reid, K. M., et al. (2022) Brain cells release calreticulin that attracts and activates microglia, and inhibits amyloid
beta aggregation and neurotoxicity, Front. Immunol., 13, 859686, https://doi.org/10.3389/fimmu.2022.859686.
MISHCHENKO et al.1838
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
65. Chen, Y., et al. (2025) Microglia efferocytosis: an emerging mechanism for the resolution of neuroinflammation
in Alzheimer’s disease, J. Neuroinflamm., 22, 96, https://doi.org/10.1186/s12974-025-03428-0.
66. Duus, K., et al. (2008) Interaction of calreticulin with amyloid beta peptide 1-42, Protein Pept. Lett., 15, 103-107,
https://doi.org/10.2174/092986608783330459.
67. Stemmer, N., et al. (2013) Generation of amyloid-β is reduced by the interaction of calreticulin with amy-
loid precursor protein, presenilin and nicastrin, PLoS One, 8, e61299, https://doi.org/10.1371/journal.pone.
0061299.
68. Lin, Q., et al. (2014) Serum calreticulin is a negative biomarker in patients with Alzheimer’s disease, Int. J. Mol.
Sci., 15, 21740-21753, https://doi.org/10.3390/ijms151221740.
69. Caldero-Escudero, E., et al. (2025) Calreticulin (crt-1) silencing reduces Aß(1)(-)(42)-induced toxicity and restores
muscle function in C. elegans, Biochim. Biophys. Acta Mol. Basis Dis., 1871, 167946, https://doi.org/10.1016/
j.bbadis.2025.167946.
70. Vilalta, A., et al. (2018) Neurophagy, the phagocytosis of live neurons and synapses by glia, contributes to brain
development and disease, FEBS J., 285, 3566-3575, https://doi.org/10.1111/febs.14323.
71. Kuang, X. L., et al. (2014) Reductions of the components of the calreticulin/calnexin quality-control system
by proteasome inhibitors and their relevance in a rodent model of Parkinson’s disease, J.Neurosci. Res., 92,
1319-1329, https://doi.org/10.1002/jnr.23413.
72. Offenburger, S. L., et al. (2018) Mutations in Caenorhabditis elegans neuroligin-like glit-1, the apoptosis pathway
and the calcium chaperone crt-1 increase dopaminergic neurodegeneration after 6-OHDA treatment, PLoS Genet.,
14, e1007106, https://doi.org/10.1371/journal.pgen.1007106.
73. Davidi, D., et al. (2020) α-Synuclein translocates to the nucleus to activate retinoic-acid-dependent gene tran-
scription, iScience, 23, 100910, https://doi.org/10.1016/j.isci.2020.100910.
74. Hejazi, M. S., et al. (2025) Annexin A1, calreticulin and high mobility group box 1 are elevated in secondary
progressive multiple sclerosis: does immunogenic cell death occur in multiple sclerosis? Bioimpacts, 15, 30264,
https://doi.org/10.34172/bi.30264.
75. Goodwin, G. H., et al. (1973) Isolation and characterisation of two calf-thymus chromatin non-histone proteins
with high contents of acidic and basic amino acids, Eur.J. Biochem., 40, 215-219, https://doi.org/10.1111/j.1432-1033.
1973.tb03188.x.
76. Tang, D., et al. (2023) The multifunctional protein HMGB1: 50 years of discovery, Nat. Rev. Immunol., 23, 824-
841, https://doi.org/10.1038/s41577-023-00894-6.
77. Li, J., et al. (2003) Structural basis for the proinflammatory cytokine activity of high mobility group box 1, Mol.
Med., 9, 37-45, https://doi.org/10.1007/BF03402105.
78. Gong, W., et al. (2010) The anti-inflammatory activity of HMGB1 A box is enhanced when fused with C-terminal
acidic tail, J.Biomed. Biotechnol., 2010, 915234, https://doi.org/10.1155/2010/915234.
79. Guazzi, S., et al. (2003) HMGB1, an architectural chromatin protein and extracellular signalling factor, has a
spatially and temporally restricted expression pattern in mouse brain, Gene Expr. Patterns, 3, 29-33, https://
doi.org/10.1016/s1567-133x(02)00093-5.
80. Fang, P., et al. (2012) HMGB1 in development and diseases of the central nervous system, Mol. Neurobiol., 45,
499-506, https://doi.org/10.1007/s12035-012-8264-y.
81. Zhao, X., et al. (2020) Regulation of neurogenesis in mouse brain by HMGB1, Cells, 9, 1714, https://doi.org/10.3390/
cells9071714.
82. Gou, X., et al. (2020) The roles of high mobility group box 1 in cerebral ischemic injury, Front. Cell Neurosci.,
14, 600280, https://doi.org/10.3389/fncel.2020.600280.
83. Banks, W. A., et al. (2023) High-mobility group box 1 (HMGB1) crosses the BBB bidirectionally, Brain Behav.
Immun., 111, 386-394, https://doi.org/10.1016/j.bbi.2023.04.018.
84. Bianchi, M. E., et al. (2005) HMG proteins: dynamic players in gene regulation and differentiation, Curr. Opin.
Genet. Dev., 15, 496-506, https://doi.org/10.1016/j.gde.2005.08.007.
85. Yang, K., et al. (2023) The relationship between HMGB1 and autophagy in the pathogenesis of diabetes and its
complications, Front. Endocrinol. (Lausanne), 14, 1141516, https://doi.org/10.3389/fendo.2023.1141516.
86. Han, Y., et al. (2025) Cytoplasmic HMGB1 promotes and interacts with BECN1 through ZNF460 to induce au-
tophagy and accelerate radioresistance in colorectal cancer cells, Front. Immunol., 16, 1642915, https://doi.org/
10.3389/fimmu.2025.1642915.
87. Chen, R., et al. (2024) HMGB1 in the interplay between autophagy and apoptosis in cancer, Cancer Lett., 581,
216494, https://doi.org/10.1016/j.canlet.2023.216494.
88. Venereau, E., et al. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflam-
matory cytokine release, J. Exp. Med., 209, 1519-1528, https://doi.org/10.1084/jem.20120189.
DAMPs IN THE CNS 1839
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
89. Kwak, M. S., et al. (2019) Peroxiredoxin-mediated disulfide bond formation is required for nucleocytoplasmic
translocation and secretion of HMGB1 in response to inflammatory stimuli, Redox Biol., 24, 101203, https://
doi.org/10.1016/j.redox.2019.101203.
90. Qaiser, H., et al. (2024) Role of thioredoxin system in regulating cellular redox status in Alzheimer’s disease, J.
Alzheimers Dis., 99, S97-S108, https://doi.org/10.3233/jad-230394.
91. Lin, H., et al. (2025) Damage-associated molecular patterns (DAMPs) in diseases: implications for therapy, Mol.
Biomed., 6, 60, https://doi.org/10.1186/s43556-025-00305-3.
92. Schiraldi, M., et al. (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by form-
ing a complex with CXCL12 and signaling via CXCR4, J. Exp. Med., 209, 551-563, https://doi.org/10.1084/jem.
20111739.
93. Liu, A., et al. (2012) Oxidation of HMGB1 causes attenuation of its pro-inflammatory activity and occurs during
liver ischemia and reperfusion, PLoS One, 7, e35379, https://doi.org/10.1371/journal.pone.0035379.
94. Apetoh, L., et al. (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemo-
therapy and radiotherapy, Nat. Med., 13, 1050-1059, https://doi.org/10.1038/nm1622.
95. Yanai, H., et al. (2012) High-mobility group box family of proteins: ligand and sensor for innate immunity,
Trends Immunol., 33, 633-640, https://doi.org/10.1016/j.it.2012.10.005.
96. Wang, H., et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice, Science, 285, 248-251, https://
doi.org/10.1126/science.285.5425.248.
97. Yang, H., et al. (2021) HMGB1 released from nociceptors mediates inflammation, Proc. Natl. Acad. Sci. USA, 118,
e2102034118, https://doi.org/10.1073/pnas.2102034118.
98. Kaya, Z., et al. (2023) Vesicular HMGB1 release from neurons stressed with spreading depolarization en-
ables confined inflammatory signaling to astrocytes, J. Neuroinflamm., 20, 295, https://doi.org/10.1186/s12974-
023-02977-6.
99. Daniels, M. J., et al. (2017) Unconventional pathways of secretion contribute to inflammation, Int. J. Mol. Sci.,
18, 102, https://doi.org/10.3390/ijms18010102.
100. Bonaldi, T., et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secre-
tion, EMBO J., 22, 5551-5560, https://doi.org/10.1093/emboj/cdg516.
101. Bell, C. W., et al. (2006) The extracellular release of HMGB1 during apoptotic cell death, Am. J. Physiol. Cell
Physiol., 291, C1318-C1325, https://doi.org/10.1152/ajpcell.00616.2005.
102. Kazama, H., et al. (2008) Induction of immunological tolerance by apoptotic cells requires caspase-dependent
oxidation of high-mobility group box-1 protein, Immunity, 29, 21-32, https://doi.org/10.1016/j.immuni.2008.05.013.
103. Wang, F., et al. (2010) Fas (CD95) induces rapid, TLR4/IRAK4-dependent release of pro-inflammatory HMGB1
from macrophages, J. Inflamm. (Lond), 7, 30, https://doi.org/10.1186/1476-9255-7-30.
104. Zheng, H., et al. (2025) RIPK3-MLKL dependent necroptosis mediates depressive-like behavior by facilitating
neuroinflammation, J. Neuroimmunol., 405, 578643, https://doi.org/10.1016/j.jneuroim.2025.578643.
105. Chen, H., et al. (2020) RIPK3 collaborates with GSDMD to drive tissue injury in lethal polymicrobial sepsis, Cell
Death Differ., 27, 2568-2585, https://doi.org/10.1038/s41418-020-0524-1.
106. Lamkanfi, M., et al. (2010) Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia, J. Immunol.,
185, 4385-4392, https://doi.org/10.4049/jimmunol.1000803.
107. Lu, B., et al. (2012) Novel role of PKR in inflammasome activation and HMGB1 release, Nature, 488, 670-674,
https://doi.org/10.1038/nature11290.
108. Yang, H., et al. (2015) High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule,
Mol. Med., 21, S6-S12, https://doi.org/10.2119/molmed.2015.00087.
109. Lu,B., et al. (2014) JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation, Proc. Natl.
Acad. Sci. USA, 111, 3068-3073, https://doi.org/10.1073/pnas.1316925111.
110. Volchuk, A., et al. (2020) Indirect regulation of HMGB1 release by gasdermin D, Nat. Commun., 11, 4561, https://
doi.org/10.1038/s41467-020-18443-3.
111. Orning, P., et al. (2018) Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin  D and
cell death, Science, 362, 1064-1069, https://doi.org/10.1126/science.aau2818.
112. Wen, Q., et al. (2019) The release and activity of HMGB1 in ferroptosis, Biochem. Biophys. Res. Commun., 510,
278-283, https://doi.org/10.1016/j.bbrc.2019.01.090.
113. Gao, X. Y., et al. (2021) Temozolomide treatment induces HMGB1 to promote the formation of glioma stem
cells via the TLR2/NEAT1/Wnt pathway in glioblastoma, Front. Cell Dev. Biol., 9, 620883, https://doi.org/10.3389/
fcell.2021.620883.
114. Hong, B., et al. (2019) Suppression of HMGB1 released in the glioblastoma tumor microenvironment reduces
tumoral edema, Mol. Ther. Oncolytics, 12, 93-102, https://doi.org/10.1016/j.omto.2018.11.005.
MISHCHENKO et al.1840
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
115. Yang, H., et al. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of
macrophage cytokine release, Proc. Natl. Acad. Sci. USA, 107, 11942-11947, https://doi.org/10.1073/pnas.1003893107.
116. Ferrara, M., et al. (2020) Oxidation of HMGB1 is a dynamically regulated process in physiological and patho-
logical conditions, Front. Immunol., 11, 1122, https://doi.org/10.3389/fimmu.2020.01122.
117. Curtin, J. F., et al. (2009) HMGB1 mediates endogenous TLR2 activation and brain tumor regression, PLoS Med.,
6, e10, https://doi.org/10.1371/journal.pmed.1000010.
118. Qu,Y., et al. (2025) Intranasal delivery of temozolomide and disulfiram in situ gel combined with copper for en-
hanced glioblastoma therapy, Colloids Surf. B Biointerf., 255, 114898, https://doi.org/10.1016/j.colsurfb.2025.114898.
119. Zhang, C., et al. (2025) Self-assembling nanoparticles orchestrate cuproptosis-immunotherapy synergy to sup-
press postoperative glioma recurrence, ACS Appl. Mater. Interfaces, 17, 64322-64339, https://doi.org/10.1021/
acsami.5c19127.
120. Yamazaki, T., et al. (2014) Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy
with TLR4 agonists, Cell Death Differ., 21, 69-78, https://doi.org/10.1038/cdd.2013.72.
121. Salminen, A. (2026) Redox-sensitive high mobility group box 1 (HMGB1) protein is a multipotent regulator in
the pathogenesis of Alzheimer’s disease, Neurochem Int, 193, 106115, https://doi.org/10.1016/j.neuint.2026.106115.
122. Szeliga, M. (2020) Peroxiredoxins in neurodegenerative diseases, Antioxidants (Basel), 9, 1203, https://
doi.org/10.3390/antiox9121203.
123. Ajoolabady, A., et al. (2025) Dual role of microglia in neuroinflammation and neurodegenerative diseases, Neu-
robiol. Dis., 216, 107133, https://doi.org/10.1016/j.nbd.2025.107133.
124. Zhang, W., et al. (2023) Role of neuroinflammation in neurodegeneration development, Signal Transduct. Target
Ther., 8, 267, https://doi.org/10.1038/s41392-023-01486-5.
125. Pechiappan, H., et al. (2026) Context-dependent release of HMGB1: cell death mode, cell type and LPS stress
drive monomer and heterocomplex formation, Mol. Med., 32, 93, https://doi.org/10.1186/s10020-026-01489-2.
126. Coleman, L. G., Jr., et al. (2018) HMGB1/IL-1β complexes in plasma microvesicles modulate immune responses
to burn injury, PLoS One, 13, e0195335, https://doi.org/10.1371/journal.pone.0195335.
127. Fassi, E. M. A., et al. (2025) A potent nonapeptide inhibitor for the CXCL12/HMGB1 heterocomplex: a com-
putational and experimental approach, Comput. Struct. Biotechnol. J., 27, 1677-1685, https://doi.org/10.1016/
j.csbj.2025.04.023.
128. Mantonico, M. V., et al. (2024) The acidic intrinsically disordered region of the inflammatory mediator HMGB1
mediates fuzzy interactions with CXCL12, Nat. Commun., 15, 1201, https://doi.org/10.1038/s41467-024-45505-7.
129. Liu, Y., et al. (2015) Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepa-
tocellular carcinoma through Toll-like receptor 9, J. Hepatol., 63, 114-121, https://doi.org/10.1016/j.jhep.2015.02.009.
130. Sweeney, M. D., et al. (2019) Blood-brain barrier: from physiology to disease and back, Physiol Rev., 99, 21-78,
https://doi.org/10.1152/physrev.00050.2017.
131. Nishibori, M., et al. (2020) High mobility group box-1 and blood-brain barrier disruption, Cells, 9, 2650, https://
doi.org/10.3390/cells9122650.
132. Wu, S., et al. (2023) Programmed cell death 10 increased blood-brain barrier permeability through HMGB1/TLR4
mediated downregulation of endothelial ZO-1 in glioblastoma, Cell Signal., 107, 110683, https://doi.org/10.1016/
j.cellsig.2023.110683.
133. Festoff, B. W., et al. (2016) HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as bio-
markers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease, J. Neuroinflamm.,
13, 194, https://doi.org/10.1186/s12974-016-0670-z.
134. Takata, K., et al. (2012) Microglial amyloid-β1-40 phagocytosis dysfunction is caused by high-mobility group
box protein-1: implications for the pathological progression of Alzheimer’s disease, Int.J. Alzheimers Dis., 2012,
685739, https://doi.org/10.1155/2012/685739.
135. Gulmammadli, N., et al. (2022) Serum sirtuin-1, HMGB1-TLR4, NF-KB and IL-6 levels in Alzheimer’s: the rela-
tion between neuroinflammatory pathway and severity of dementia, Curr. Alzheimer Res., 19, 841-848, https://
doi.org/10.2174/1567205020666221226140721.
136. Gaikwad, S., et al. (2021) Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropa-
thology linked to Alzheimer’s disease and frontotemporal dementia, Cell Rep., 36, 109419, https://doi.org/10.1016/
j.celrep.2021.109419.
137. Li, W., et al. (2025) Roles of the receptor for advanced glycation end products and its ligands in the pathogen-
esis of Alzheimer’s disease, Int. J. Mol. Sci., 26, 403, https://doi.org/10.3390/ijms26010403.
138. Fang, F., et al. (2010) RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumula-
tion, and impaired learning/memory in a mouse model of Alzheimer’s disease, FASEB J., 24, 1043-1055, https://
doi.org/10.1096/fj.09-139634.
DAMPs IN THE CNS 1841
BIOCHEMISTRY (MOSCOW) Vol. 91 No. 10 2026
139. Fang, F., et al. (2018) RAGE mediates Aβ accumulation in a mouse model of Alzheimer’s disease via modulation
of β- and γ-secretase activity, Hum. Mol. Genet., 27, 1002-1014, https://doi.org/10.1093/hmg/ddy017.
140. Santoro, M., et al. (2016) In-vivo evidence that high mobility group box 1 exerts deleterious effects in the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson’s disease which can be attenuated by glycyr-
rhizin, Neurobiol. Dis., 91, 59-68, https://doi.org/10.1016/j.nbd.2016.02.018.
141. Lindersson, E. K., et al. (2004) alpha-Synuclein filaments bind the transcriptional regulator HMGB-1, Neuroreport,
15, 2735-2739.
142. Gao, H. M., et al. (2011) HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives
progressive neurodegeneration, J. Neurosci., 31, 1081-1092, https://doi.org/10.1523/jneurosci.3732-10.2011.
143. Guan,Y., et al. (2018) HMGB1 promotes the starvation-induced autophagic degradation of α-synuclein in SH-SY5Y
cells Atg 5-dependently, Life Sci., 202, 1-10, https://doi.org/10.1016/j.lfs.2018.03.031.
144. Paudel, Y. N., et al. (2020) Implication of HMGB1 signaling pathways in amyotrophic lateral sclerosis (ALS):
From molecular mechanisms to pre-clinical results, Pharmacol. Res., 156, 104792, https://doi.org/10.1016/
j.phrs.2020.104792.
145. Casula, M., et al. (2011) Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue, Neuro-
science, 179, 233-243, https://doi.org/10.1016/j.neuroscience.2011.02.001.
146. Lee, J. D., et al. (2019) Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the
SOD1(G93A) mouse model of amyotrophic lateral sclerosis, J Neuroinflammation, 16, 45, https://doi.org/10.1186/
s12974-019-1435-2.
147. Lee, J. Y., et al. (2015) Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse model
of amyotrophic lateral sclerosis, J. Neuroinflamm., 12, 90, https://doi.org/10.1186/s12974-015-0310-z.
148. Feng, Y., et al. (2025) HMGB1 mediates microglia-astrocyte/neuron crosstalk and pyroptosis by the TLR4/NF-κB
pathway in multiple sclerosis, Front. Biosci. (Landmark Ed), 30, 37838, https://doi.org/10.31083/fbl37838.
149. Andersson, A., et al. (2008) Pivotal advance: HMGB1 expression in active lesions of human and experimental
multiple sclerosis, J.Leukoc. Biol., 84, 1248-1255, https://doi.org/10.1189/jlb.1207844.
150. Nishibori,M., et al. (2019) Anti-HMGB1 monoclonal antibody therapy for a wide range of CNS and PNS diseases,
J. Pharmacol. Sci., 140, 94-101, https://doi.org/10.1016/j.jphs.2019.04.006.
Publisher’s Note. Pleiades Publishing remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations. AI tools may have been used in the translation or editing of this article.